CEO and officer selling at InMed Pharmaceuticals (C:IN)

Eric Ashley Adams, CEO and Director, disposed of 800,000 Common Shares on a direct ownership basis at prices ranging from $1.999 to $2.281 between January 8th, and 9th, 2018. This represents a $1,762,901 divestment of the company's shares and an account share holdings change of -99.0%.

Alexandra Diane Janet Mancini, a Senior Officer, disposed of 40,000 Common Shares on a direct ownership basis at a price of $2.162 on January 8th, 2018. This represents a $86,492 divestment of the company's shares and an account share holdings change of -40.0%.

InMed Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).